4.4 Review

Platelets in COVID-19 disease: friend, foe, or both?

期刊

PHARMACOLOGICAL REPORTS
卷 -, 期 -, 页码 -

出版社

SPRINGER HEIDELBERG
DOI: 10.1007/s43440-022-00438-0

关键词

COVID-19; Platelets; Endothelial barrier; Pulmonary circulation

资金

  1. National Science Centre, Poland [2021/41/B/NZ5/02374]
  2. FNP (Foundation for Polish Science) - European Union under the European Regional Development Fund
  3. European Union under the European Regional Development Fund [POIR.04.04.00-00-5CAC/17-00]

向作者/读者索取更多资源

Immuno-thrombosis in COVID-19 leads to platelet activation and coagulopathy. Antiplatelet therapy may not have a major impact on mortality in hospitalized COVID-19 patients despite the increased risk of thrombotic complications. Platelets play a role in maintaining endothelial barrier integrity, particularly in the lungs, and inhibiting platelet function may diminish the protective aspect of platelet activity. Understanding platelet-dependent mechanisms is crucial in designing antiplatelet therapeutic strategies that target pro-thrombotic platelet activity without affecting the vaso-protective function in the pulmonary endothelial barrier during host defense.
Immuno-thrombosis of COVID-19 results in the activation of platelets and coagulopathy. Antiplatelet therapy has been widely used in COVID-19 patients to prevent thrombotic events. However, recent analysis of clinical trials does not support the major effects of antiplatelet therapy on mortality in hospitalized COVID-19 patients, despite the indisputable evidence for an increased risk of thrombotic complications in COVID-19 disease. This apparent paradox calls for an explanation. Platelets have an important role in sensing and orchestrating host response to infection, and several platelet functions related to host defense response not directly related to their well-known hemostatic function are emerging. In this paper, we aim to review the evidence supporting the notion that platelets have protective properties in maintaining endothelial barrier integrity in the course of an inflammatory response, and this role seems to be of particular importance in the lung. It might, thus, well be that the inhibition of platelet function, if affecting the protective aspect of platelet activity, might diminish clinical benefits resulting from the inhibition of the pro-thrombotic phenotype of platelets in immuno-thrombosis of COVID-19. A better understanding of the platelet-dependent mechanisms involved in the preservation of the endothelial barrier is necessary to design the antiplatelet therapeutic strategies that inhibit the pro-thrombotic activity of platelets without effects on the vaso-protective function of platelets safeguarding the pulmonary endothelial barrier during multicellular host defense in pulmonary circulation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据